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Pathogenic ELN gene mutations (ELN, MIM#130160) cause
AD Supravalvular Aortic Stenosis (SVAS) a congenital narrow-
ing of the ascending aorta, and Cutis Laxa (CL) characterised
by inelastic, loose-hanging skin. Variable phenotype and pene-
trance is apparent. Pathogenic ELN variants result in loss of
function and include frameshift (most common), nonsense,
splice site and missense variants. The well characterised contig-
uous gene deletion syndrome, Williams-Beuren syndrome
includes SVAS and encompasses at least 114kb on 7q11.23
including the ELN gene; however, there are only 5 case
reports of CNVs within ELN (single or multiple exons).
Bristol Genetics Laboratory provides a UKGTN approved
service for ELN gene sequencing (33 coding exons). In three
years, 52 UK and foreign patients with SVAS, CL or features
such as pulmonary artery stenosis and aortic dilation have
been tested. 18/52 (34%) patients were heterozygous for a
likely pathogenic variant including frameshift (6), nonsense
(4), splice (4), and missense (4). 12 of these cases were novel
variants, 5 are supported by segregation analysis and 1 is
sporadic. The remaining novel variants are classed as possibly
pathogenic as they are phenotypically compatible.
12/35 patients negative on sequencing have so far been
screened for CNVs by MLPA (MRC Holland) covering the
Williams-Beuren syndrome region, including 10 exons of the
ELN gene (1, 3, 4, 6, 9, 16, 20, 26, 27 and 33) and in addi-
tion a bespoke MLPA assay including probes for exons 28 to
30, 32 and 3’UTR.
4/12 (33%) patients have a heterozygous deletion within
the ELNgene. A mother and daughter with pulmonary stenosis
and an extended family history have a deletion spanning
exons 30 to 33. This deletion was also identified in another
patient with SVAS and arteriopathy. A deletion of the 5’ end
of the gene, involving at least exon 1 (but not exon 3) was
identified in an infant with SVAS and pulmonary branch
stenosis, and a deletion involving the entire coding region of
the ELN gene and at least the first two exons of the adjacent
3’ gene LIMK1 was detected in a neonate who died at 2
months with SVAS, pulmonary stenosis and mild hypoplasia
with PDA. The deletion was detected in this patient’s father
who consequentially was found to have an aortic regurgitation
and in a subsequent pregnancy of this family which was lost
at 31 weeks with pulmonary stenosis and significant aortic
stenosis
MLPA analysis has enhanced the clinical utility of this serv-
ice giving an increased diagnostic yield in patients with SVAS
and CL and related presentations.
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Background Endothelial dysfunction is a key player in cardio-
vascular disease (CVD) complications and novel drugs are
required to treat this pathological process. Glycosaminoglycans
(GAGs) are key molecules that regulate signalling in many bio-
logical processes and drugs that mimic their structure could be
a novel source of therapeutics to target specific CVD
pathways.
Purpose We have synthesised a set of four glycomimetic com-
pounds and our objective was to determine whether they
could activate protective pathways in endothelial cells sub-
jected to fatty acid-induced endothelial dysfunction.
Methods Glycomimetics, C1-C4, were synthesised by the step-
wise transformation of 2,5-dihydroxybenzoic acid to a range
of 2,5-substituted benzoic acid derivatives, incorporating the
key sulphate groups to mimic heparan sulphate. Human
Umbilical Vein Endothelial Cells (HUVECs) were treated with
glycomimetics (1ÂmM) in the presence or absence of the free
fatty acid, palmitate. DAF-2 and H2DCF-DA assays were used
to determine NO and reactive oxygen species (ROS) produc-
tion, respectively. Lipid peroxidation colorimetric and antioxi-
dant enzyme activity ssays were also carried out. RT-PCR and
western blotting were utilised to measure Akt, eNOS, Nrf-2,
NQO-1 and HO-1 expression. Endothelial function was deter-
mined ex vivo using acetylcholine-induced endothelium-
dependent relaxation in mouse thoracic aortic rings by wire
myography.
Results All four glycomimetics protected against palmitate-
induced oxidative stress and enhanced NO production in vitro
via upregulation of Akt/eNOS signalling, activation of the
Nrf2/ARE pathway and down-regulation of ROS-induced lipid
peroxidation. Under palmitate-induced oxidative stress, ex vivo
endothelium-dependent relaxation was significantly enhanced
by all four glycomimetics. Furthermore, the glycomimetics did
not induce HUVEC activation, as determined by lack of
ICAM-1 protein.
Conclusion We have developed a new set of small molecule
glycomimetics that do not activate ECs and protect against
free fatty acid-induced endothelial dysfunction both in vitro
and ex vivo. Future work will focus on developing the glyco-
mimetics into drug-like therapies that target endothelial
damage.
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Background Human induced pluripotent stem (iPS) cell-derived
endothelial cells (ECs) hold clear potential for therapeutic
angiogenesis as a novel strategy for ischaemic disease.
Recently, our group has developed a novel method for direct
reprogramming of partial iPS (PiPS) cells, which unlike iPS
cells, are generated before pluripotency so do not form
tumours. Importantly, PiPS cells may be differentiated into
ECs with characteristic morphology and pro-angiogenic
actions, which in vitro and in vivo studies have demonstrated
are comparable to mature ECs with regard to their capability
of forming vascular-like tubes and re-endothelialisation of
ischaemic tissue. It is well established that oxidative stress and
reactive oxygen species (ROS), which are characteristic features
of ischaemic disease, are important regulators of both endo-
thelial and stem cell biology, with recent evidence suggesting a
key role for NADPH oxidases. Notably, we have previously
identified a key role for the Nox4 isoform in regulating
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